The Phase II portion is seeking to establish safety and efficacy of the company’s HER2 breast cancer therapy in combination ...

Telix is in a strong financial position with net cash of AUD 140 million as of December 2024. We forecast free cash flow averaging 87% of net income over the next 10 years, and in the absence of major ...

Shannin Desroches fought for a diagnosis after being dismissed. Now she tells PEOPLE that she's been given a 5% chance of ...

Kansas frontman Ronnie Platt's cancer diagnosis led the rock band to cancel upcoming shows. Platt is battling thyroid cancer ...

A high omega-3, low omega-6 diet with fish oil led to a significant reduction in a biomarker for prostate cancer progression ...

Purple Biotech has entered a Phase II trial with its small molecule drug, NT219, focusing on patients with ...

A new blood-based test could diagnose pancreatic cancer much earlier, improving outcomes for people with the disease.

Aston University is collaborating in research to develop an injectable paste which could treat bone cancer.

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, continues to make good progress in 2025 with key regulatory and ...

(UroToday.com) The 2025 GU ASCO annual meeting featured a prostate cancer session and a presentation by Joseph Allen discussing PSA response and survival based on metastatic site in patients with ...